Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1

Clinical trial NCT02034981 · COMPLETED

Trial details

NCT number: NCT02034981
Sponsor: UNICANCER
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Hematologic Cancers Solid Tumors Metastatic Cancer

Start date: 2013-08-01
Primary completion: 2019-06-01
Enrollment: 246

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.